Following April’s trade deficit data, which showed a complete freefall in trade during the “Liberation Day” tariff month, May’s trade deficit rose by 18.7% on a monthly basis to $71.5 billion, according to the Bureau of Economic Analysis (BEA).
Tariffs were supposed to be inflationary, but so far, they’ve been proven wrong. Inflation over the last several months was not caused by 10% tariffs on Southeast Asia, nor by the short-lived 145% tariffs on China.
The Senate’s decision to remove the FEOC Excise Tax and weaken FEOC restrictions is a blatant giveaway to the Chinese Communist Party’s solar industry.
Any Senator who supports an amendment to remove or weaken the FEOC Excise Tax is directly endorsing China’s solar industry—dominated by companies using slave labor, powered by coal, and compromised by severe cybersecurity risks.
Last year, it wasn’t even in the Top 10. This year, they’re number one. General Motors was ranked as the most China-exposed U.S. multinational by Strategy Risks, a political risk consultancy in New York.
CPA strongly endorses the FEOC Excise Tax in the Senate reconciliation bill as a critical step in protecting America’s solar manufacturing industry from reliance on subsidized and compromised Chinese components.
The U.S. kitchen cabinet industry has a long and storied history, deeply rooted in small- to medium-sized businesses that form the backbone of American manufacturing.
CPA warned that the Senate version of President Trump’s reconciliation bill—known as the One Big Beautiful Bill—contains a critical loophole in both the Section 48E investment tax credit and 45Y production tax credit in the Inflation Reduction Act (IRA), creating an unintended but dangerous giveaway to China’s solar industry.
The two Trump Administrations have reshaped the debate on U.S. trade policy. For the first time in decades, U.S. officials are no longer endorsing the “free trade” orthodoxy that has contributed to the erosion of its manufacturing sector. Instead, tariffs are now the centerpiece of U.S. plans to repatriate supply chains and reindustrialize America.
America is facing a growing crisis in its medical system — not from a lack of talent or innovation, but from a breakdown in the control, safety and supply of essential medicine. Our growing reliance on imports is now driving serious drug shortages, destabilizing supply chains and increasingly making medications unsafe.
